NCT04683965 2022-08-02
Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
Clinical Trials
7 trialsNCT03843853 2022-07-25
Pemetrexed and S-1 in Combination With Bevacizumab in Refractory Colorectal Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Withdrawn
NCT02588781 2022-06-15
Pemetrexed Alone as Salvage Treatment in Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy: A Phase II Single Arm Prospective Study
Samsung Medical Center
Phase 2 Unknown
NCT02723578 2020-01-13
Pemetrexed and Erlotinib for Metastatic Colorectal Cancer
Yonsei University
Phase 2 Completed
NCT01109615 2012-04-19
PG
Vejle Hospital
Phase 2 Terminated
NCT00191984 2011-01-05
A Study of the Combination of Pemetrexed and Irinotecan Every Two Weeks in Metastatic Colorectal Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00034619 2006-07-19
A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.
Eli Lilly and Company
Phase 2 Completed